Effect of the COVID-19 pandemic on Vogt-Koyanagi-Harada disease.
COVID-19
Pandemics
Prevalence
Sex ratio
Visual acuity
Vogt–Koyanagi–Harada disease
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
08 Jun 2024
08 Jun 2024
Historique:
received:
24
02
2024
accepted:
04
06
2024
medline:
9
6
2024
pubmed:
9
6
2024
entrez:
8
6
2024
Statut:
epublish
Résumé
To determine the disease prevalence rate and clinical characteristics of Vogt-Koyanagi-Harada (VKH) disease among new patients before and after the declaration of a state of emergency (April 7, 2020) in Japan. New patients and patients with newly diagnosed VKH disease were categorized into "Before" and "After" groups based on the initial visit. The prevalence rate, sex ratio, and age of patients newly diagnosed with VKH were compared between the groups. Best-corrected visual acuity (BCVA) and recurrence rates were compared among 59 patients observed for > 12 months after receiving pulse steroid therapy. For reference, we also examined the prevalence rate of patients newly diagnosed with acute angle closure (AAC) in the Before and After groups. The prevalence rates of VKH disease among newly diagnosed patients (P < 0.05) or patients with AAC (P < 0.001) were significantly higher in the After group. No significant differences in sex ratio or age of VKH disease were observed in both groups. BCVA and recurrence rates showed no significant differences. The COVID-19 pandemic increased the prevalence of VKH disease among new patients compared with that of AAC. However, the clinical features of VKH disease were unlikely affected by the COVID-19 pandemic.
Identifiants
pubmed: 38851824
doi: 10.1038/s41598-024-63957-1
pii: 10.1038/s41598-024-63957-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
13211Informations de copyright
© 2024. The Author(s).
Références
Zhu, N. et al. A novel coronavirus from patients with pneumonia in China. N. Engl. J. Med. 382, 727–733 (2020).
doi: 10.1056/NEJMoa2001017
pubmed: 31978945
pmcid: 7092803
Alqudah, A. A., Al Dwairi, R. A., Alqudah, N. M. & Abumurad, S. K. COVID-19 lockdown and eye Injury: A case series from Jordan. Int. Med. Case Rep. J. 13, 493–501 (2020).
pubmed: 33116940
pmcid: 7553262
Stedman, E. N., Jefferis, J. M. & Tan, J. H. Ocular trauma during the COVID-19 lockdown. Ophthalmic Epidemiol. 28, 458–460 (2021).
doi: 10.1080/09286586.2021.1875012
pubmed: 33467961
Binotti, W. & Hamrah, P. COVID-19-related conjunctivitis review: Clinical features and management. Ocul. Immunol. Inflamm. 31, 778–784 (2023).
doi: 10.1080/09273948.2022.2054432
pubmed: 35394858
Riotto, E. et al. A COVID-19-related retinopathy case report. Case Rep. Ophthalmol. 13, 297–304 (2022).
doi: 10.1159/000524195
pubmed: 35702520
pmcid: 9149546
Behera, G., Gokhale, T. & Babu, K. R. Acute endothelial graft rejection following COVID-19 infection. Cureus 13, e19084. https://doi.org/10.7759/cureus.19084 (2021).
doi: 10.7759/cureus.19084
pubmed: 34722015
pmcid: 8550024
Marziali, E., Pasqualetti, R., Bacci, G., de Libero, C. & Caputo, R. Acute rejection following COVID-19 vaccination in penetrating keratoplasty in a young male—A case report and review of literature. Ocul. Immunol. Inflamm. 31, 1226–1229 (2023).
doi: 10.1080/09273948.2022.2106248
pubmed: 35914312
Behera, G. et al. Bilateral optic neuritis and facial palsy following COVID-19 infection. Cureus 14, e28735. https://doi.org/10.7759/cureus.28735 (2022).
doi: 10.7759/cureus.28735
pubmed: 36072783
pmcid: 9440666
Manoharan, A., Agarwal, A. & Dutta Majumder, P. Acute retinal necrosis: A Covid-19 perspective. Ocul. Immunol. Inflamm. 31, 1270–1272 (2023).
doi: 10.1080/09273948.2022.2159842
pubmed: 36637990
Abdul-Salam State, S. E., Sfredel, V., Mocanu, C. L., Albu, C. V. & Bălășoiu, A. T. Optic neuropathies post-Covid 19—Review. Rom. J. Ophthalmol. 66, 289–298 (2022).
pubmed: 36589322
pmcid: 9773110
Hawley, L. & Han, L. S. Acute macular neuroretinopathy following COVID-19 infection. N. Z. Med. J. 135, 105–107 (2022).
pubmed: 36201735
Ng, X. L. et al. Ocular adverse events after COVID-19 vaccination. Ocul. Immunol. Inflamm. 29, 1216–1224 (2021).
doi: 10.1080/09273948.2021.1976221
pubmed: 34559576
Anthony, E., Rajamani, A., Baskaran, P. & Rajendran, A. Vogt Koyanagi Harada disease following a recent COVID-19 infection. Indian J. Ophthalmol. 70, 670–672 (2022).
doi: 10.4103/ijo.IJO_2550_21
pubmed: 35086262
pmcid: 9023905
Shariati, M. M. et al. Uveitis including Vogt–Koyanagi–Harada syndrome following inactive Covid-19 vaccination: A case series. J. Ophthalmic Inflamm. Infect. 13, 26. https://doi.org/10.1186/s12348-023-00347-0 (2023).
doi: 10.1186/s12348-023-00347-0
pubmed: 37204647
pmcid: 10198016
Majumder, P. D., Sadhu, S., González-López, J. J. & Mochizuki, M. A COVID-19 perspective of Vogt–Koyanagi–Harada disease. Indian J. Ophthalmol. 71, 2587–2591 (2023).
doi: 10.4103/IJO.IJO_172_23
Accorinti, M., Saturno, M. C. & Manni, P. Vogt–Koyanagi–Harada relapse after COVID-19 vaccination. Ocul. Immunol. Inflamm. 30, 1228–1233 (2022).
doi: 10.1080/09273948.2022.2027469
pubmed: 35201950
Saraceno, J. J. F., Souza, G. M., Dos Santos Finamor, L. P., Nascimento, H. M. & Belfort, R. Vogt–Koyanagi–Harada syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine. Int. J. Retina Vitreous 7, 49. https://doi.org/10.1186/s40942-021-00319-3 (2021).
doi: 10.1186/s40942-021-00319-3
pubmed: 34462013
pmcid: 8404022
Joo, C. W., Kim, Y. K. & Park, S. P. Vogt–Koyanagi–Harada disease following mRNA-1273 (Moderna) COVID-19 vaccination. Ocul. Immunol. Inflamm. 30, 1250–1254 (2022).
doi: 10.1080/09273948.2022.2053547
pubmed: 35404752
Yasaka, Y. et al. A multicenter study of ocular inflammation after COVID-19 vaccination. Jpn. J. Ophthalmol. 67, 14–21 (2023).
doi: 10.1007/s10384-022-00962-9
pubmed: 36417027
Yoshino, N. et al. Vogt–Koyanagi–Harada disease associated with influenza A virus infection. Intern. Med. 57, 1661–1665 (2018).
doi: 10.2169/internalmedicine.9819-17
pubmed: 29321438
pmcid: 6028674
Bai, X. & Hua, R. Case report: Vogt–Koyanagi–Harada syndrome mimicking acute angle-closure glaucoma in a patient infected with human immunodeficiency virus. Front. Med. (Lausanne) 8, 752002. https://doi.org/10.3389/fmed.2021.752002 (2021).
doi: 10.3389/fmed.2021.752002
pubmed: 35096859
Priya, D., Sudharshan, S. & Biswas, J. Management of a rare presentation of Vogt–Koyanagi–Harada disease in human immunodeficiency virus/acquired immunodeficiency disease syndrome patient. Indian J. Ophthalmol. 65, 413–416 (2017).
doi: 10.4103/ijo.IJO_544_16
pubmed: 28574002
pmcid: 5565895
Al-Muammar, A. M., Al-Mudhaiyan, T. M., Al Otaibi, M., Abdo, A. & Abu El-Asrar, A. M. Vogt–Koyanagi–Harada disease occurring during interferon-alpha and ribavirin therapy for chronic hepatitis C virus infection. Int. Ophthalmol. 30, 611–613 (2010).
doi: 10.1007/s10792-010-9357-0
pubmed: 20177954
Sood, A. B., O’Keefe, G., Bui, D. & Jain, N. Vogt–Koyanagi–Harada disease associated with hepatitis B vaccination. Ocul. Immunol. Inflamm. 27, 524–527 (2019).
doi: 10.1080/09273948.2018.1483520
pubmed: 29953303
Dogan, B., Erol, M. K. & Cengiz, A. Vogt–Koyanagi–Harada disease following BCG vaccination and tuberculosis. Springerplus 5, 603. https://doi.org/10.1186/s40064-016-2223-4 (2016).
doi: 10.1186/s40064-016-2223-4
pubmed: 27247899
pmcid: 4864801
Murtaza, F., Pereira, A., Mandelcorn, M. S. & Kaplan, A. J. Vogt–Koyanagi–Harada disease following influenza vaccination. Am. J. Ophthalmol. Case Rep. 26, 101516. https://doi.org/10.1016/j.ajoc.2022.101516 (2022).
doi: 10.1016/j.ajoc.2022.101516
pubmed: 35464684
pmcid: 9020092
Manni, P., Saturno, M. C. & Accorinti, M. Vogt–Koyanagi–Harada disease and COVID. J. Clin. Med. 12, 6242. https://doi.org/10.3390/jcm12196242 (2023).
doi: 10.3390/jcm12196242
pubmed: 37834885
pmcid: 10573236
Lauermann, P. et al. There is no intraocular affection on a SARS-CoV-2-infected ocular surface. Am. J. Ophthalmol. Case Rep. 20, 100884. https://doi.org/10.1016/j.ajoc.2020.100884 (2020).
doi: 10.1016/j.ajoc.2020.100884
pubmed: 32839739
pmcid: 7439011
Oren, B. & Kocabas, D. O. Assessment of corneal endothelial cell morphology and anterior segment parameters in COVID-19. Ther. Adv. Ophthalmol. 14, 25158414221096057. https://doi.org/10.1177/25158414221096057 (2022).
doi: 10.1177/25158414221096057
pubmed: 35574183
pmcid: 9092573
Fırat, M. & Kobat, S. How are central foveal and choroidal thickness affected in patients with mild COVID-19 infection?. Bosn. J. Basic Med. Sci. 21, 782–786 (2021).
pubmed: 34157253
pmcid: 8554697
Gokmen, O. & Ozgur, G. Effects of COVID-19 infection on retinal vascular density and choroidal thickness measured by optical coherence tomography angiography. Photodiagnosis Photodyn. Ther. 44, 103859. https://doi.org/10.1016/j.pdpdt.2023.103859 (2023).
doi: 10.1016/j.pdpdt.2023.103859
pubmed: 37871811
Sakamoto, T. et al. Increased incidence of endophthalmitis after vitrectomy relative to face mask wearing during COVID-19 pandemic. Br. J. Ophthalmol. 107, 1472–1477 (2023).
doi: 10.1136/bjophthalmol-2022-321357
pubmed: 35728937
Lulla, N. H., Loganathan, M., Balan, V. G. M. & Swathi, S. Dry eye among medical students before and during COVID-19. Indian J. Ophthalmol. 71, 1468–1471 (2023).
doi: 10.4103/IJO.IJO_2786_22
pubmed: 37026284
pmcid: 10276713
Lima-Fontes, M. et al. Microbiological profile of infectious keratitis during Covid-19 pandemic. Clin. Ophthalmol. 17, 535–543 (2023).
doi: 10.2147/OPTH.S395877
pubmed: 36798798
pmcid: 9926925
Fontes Junior, V. C., Fernandes, A. G., Morales, M. C. & Belfort Neto, R. The impact of the COVID-19 pandemic on the diagnosis and treatment of ocular cancer. Arq. Bras. Oftalmol. 86, 127–130 (2023).
pubmed: 35417515
Park, H. S. et al. Retinal artery and vein occlusion risks after coronavirus disease 2019 or coronavirus disease 2019 vaccination. Ophthalmology 131, 322–332. https://doi.org/10.1016/j.ophtha.2023.09.019 (2023).
doi: 10.1016/j.ophtha.2023.09.019
pubmed: 37739232
Zhang, J., Tecson, K. M. & McCullough, P. A. Endothelial dysfunction contributes to COVID-19-associated vascular inflammation and coagulopathy. Rev. Cardiovasc. Med. 21, 315–319 (2020).
doi: 10.31083/j.rcm.2020.03.126
pubmed: 33070537
Nakayama, M., Keino, H., Watanabe, T. & Okada, A. A. Clinical features and visual outcomes of 111 patients with new-onset acute Vogt–Koyanagi–Harada disease treated with pulse intravenous corticosteroids. Br. J. Ophthalmol. 103, 274–278 (2019).
doi: 10.1136/bjophthalmol-2017-311691
pubmed: 29666121
Yang, P. et al. Comparison of clinical features and visual outcome between sympathetic ophthalmia and Vogt–Koyanagi–Harada disease in Chinese patients. Ophthalmology 126, 1297–1305 (2019).
doi: 10.1016/j.ophtha.2019.03.049
pubmed: 30959067
Zhao, C. et al. Longitudinal observation of sub-retinal fibrosis in Vogt–Koyanagi–Harada disease. BMC Ophthalmol. https://doi.org/10.1186/s12886-018-0670-0 (2018).
doi: 10.1186/s12886-018-0670-0
pubmed: 30587181
pmcid: 6307285
Jin, K. et al. A novel risk stratification-based immunomodulatory treatment strategy for Vogt–Koyanagi–Harada disease. Am. J. Ophthalmol. 262, 25–33 (2024).
doi: 10.1016/j.ajo.2024.01.035
pubmed: 38369223
Read, R. W. et al. Revised diagnostic criteria for Vogt–Koyanagi–Harada disease: Report of an international committee on nomenclature. Am. J. Ophthalmol. 131, 647–652 (2001).
doi: 10.1016/S0002-9394(01)00925-4
pubmed: 11336942
Muto, T. & Machida, S. Chronological changes of the anterior chamber structure, axial length, and refraction in patients with Vogt–Koyanagi–Harada disease. Eur. J. Ophthalmol. 31, 491–496 (2021).
doi: 10.1177/1120672120902037
pubmed: 31973595